Over 5 Million Doses Administered Worldwide1*
Choose more than 20 years of clinical experience1†
Sandostatin® LAR® is the most prescribed and most studied medical therapy in the treatment of acromegaly. Sandostatin® LAR® has a well-established safety profile backed by more than a decade of clinical use.
- Over 6,200 published articles2‡
- Over 600 clinical trials1‡
- Over 1,000,000 patient-years of experience1*
*Includes immediate-release Sandostatin® and Sandostatin® LAR® for all approved indications.
†For all approved indications.
‡Combined experience with immediate-release Sandostatin® and Sandostatin® LAR®.
Sandostatin® offers the benefit of 1 type of therapy, available in 2 formulations. Sandostatin® Injection, approved for use since 1987, is a subcutaneous (s.c.) formulation of the drug octreotide acetate.1
Sandostatin® LAR®, the long-acting formulation of this drug, was approved for use globally in 1997 and maintains all of the clinical and pharmacological characteristics of the immediate-release dosage form of s.c. Sandostatin® Injection. Sandostatin® LAR® provides the added feature of convenient, once-monthly administration and has a well-tolerated safety profile backed by more than a decade of clinical use.3-5
Did you know? Sandostatin® LAR® works at the site of the tumor to regulate GH secretion and cell growth.6 Learn more.
1. Data on file. Novartis Pharmaceuticals Corp. 2. PubMed. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/pubmed/?term=octreotide. Accessed August 24, 2014. 3. Sandostatin® LAR® Summary of Product Characteristics. Novartis Pharma AG. 2016. 4. Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J. 2006;82(963):24-30. 5. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88(7):3090-3098. 6. Paisley AN, Trainer PJ. Medical treatment in acromegaly. Curr Opin Pharmacol. 2003;3(6):672-677.
Please see the Summary of Product Characteristics.